

For immediate release: 10 May 2006

Akers Biosciences, Inc
("Akers Biosciences" or the "Company")

Result of AGM

Akers Biosciences, the United States based developer, manufacturer, and supplier of rapid, point of care screening and testing products, is pleased to announce that, at the Annual General Meeting of the Company held yesterday at 2.30pm EDT, all resolutions were passed.

The Directors are pleased with the levels of demand for both the PIFA[®] Heparin/ Platelet Factor-4 Rapid Assay, which is now being used in over 400 hospitals in the U.S, and the recently FDA approved rapid alcohol breathalyzers.

For further information, please contact,

Dr. Ray Akers	Chief Executive Officer, Akers Biosciences, Inc.	020 7917 9476
Paul Freedman	Chief Financial Officer, Akers Biosciences, Inc.	001 856 848 8698
Bill Roberts	CTC, Inc.	001 937 434 2700
Ben Simons	Hansard Communications	020 7245 1100

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.